Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

8.720 -1.010 (-10.38%)

Delayed Quote Updated: 12:33 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bicara Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 23, 2025

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

May 23, 2025

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook ↗

May 23, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

May 23, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results ↗

May 23, 2025

Via Benzinga

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics ↗

May 23, 2025

The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.

Via Investor's Business Daily

Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 23, 2025

Via Benzinga

Discover the top movers in Friday's pre-market session. ↗

May 23, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 23, 2025

Via Benzinga

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

May 22, 2025

Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset

From Bicara Therapeutics Inc.

Via GlobeNewswire

Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday ↗

May 16, 2025

Via Benzinga

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

April 28, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

April 17, 2025

Via Benzinga

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 27, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 25, 2025

Via Benzinga

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

March 25, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

February 24, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

February 11, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

January 27, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket ↗

January 17, 2025

Via Benzinga

BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

December 09, 2024

Via Benzinga

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

November 11, 2024

From Bicara Therapeutics Inc.

Via GlobeNewswire

This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

October 08, 2024

Via Benzinga

This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

October 08, 2024

Via Benzinga

StandardAero Surges In Market Debut ↗

October 06, 2024

Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at...

Via Talk Markets

Topics Initial Public Offering

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 16, 2024

From Bicara Therapeutics Inc.

Via GlobeNewswire

Trio Of Biotech IPOs Climb In Debut ↗

September 15, 2024

A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public...

Via Talk Markets

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.